173 related articles for article (PubMed ID: 23474757)
1. Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.
Wetterskog D; Shiu KK; Chong I; Meijer T; Mackay A; Lambros M; Cunningham D; Reis-Filho JS; Lord CJ; Ashworth A
Oncogene; 2014 Feb; 33(8):966-76. PubMed ID: 23474757
[TBL] [Abstract][Full Text] [Related]
2. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Hong YS; Kim J; Pectasides E; Fox C; Hong SW; Ma Q; Wong GS; Peng S; Stachler MD; Thorner AR; Van Hummelen P; Bass AJ
PLoS One; 2014; 9(10):e109440. PubMed ID: 25350844
[TBL] [Abstract][Full Text] [Related]
3. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
5. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
[TBL] [Abstract][Full Text] [Related]
6. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
7. Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Li G; Wang X; Hibshoosh H; Jin C; Halmos B
PLoS One; 2014; 9(9):e106349. PubMed ID: 25238247
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
9. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
10. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
11. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Xia W; Liu Z; Zong R; Liu L; Zhao S; Bacus SS; Mao Y; He J; Wulfkuhle JD; Petricoin EF; Osada T; Yang XY; Hartman ZC; Clay TM; Blackwell KL; Lyerly HK; Spector NL
Mol Cancer Ther; 2011 Aug; 10(8):1367-74. PubMed ID: 21673090
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
Kancha RK; von Bubnoff N; Bartosch N; Peschel C; Engh RA; Duyster J
PLoS One; 2011; 6(10):e26760. PubMed ID: 22046346
[TBL] [Abstract][Full Text] [Related]
13. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.
Zhang D; Pal A; Bornmann WG; Yamasaki F; Esteva FJ; Hortobagyi GN; Bartholomeusz C; Ueno NT
Mol Cancer Ther; 2008 Jul; 7(7):1846-50. PubMed ID: 18644997
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Xia W; Husain I; Liu L; Bacus S; Saini S; Spohn J; Pry K; Westlund R; Stein SH; Spector NL
Cancer Res; 2007 Feb; 67(3):1170-5. PubMed ID: 17283152
[TBL] [Abstract][Full Text] [Related]
15. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
[TBL] [Abstract][Full Text] [Related]
16. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
17. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
18. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
